Pre-market hot trades in US stocks: Lakewood-Amedex Biotherapeutics up 54.51% in pre-market; Galaxy Digital up 3.00% in pre-market

Pre-market Hot Trades in US Stocks Lakewood-Amedex Biotherapeutics pre-market up 54.51%. No significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Galaxy Digital pre-market up 3.00%. Based on recent key news: On April 29, Galaxy Digital announced its Q1 2026 financial report, with a net loss of $216 million, mainly affected by the decline in the cryptocurrency market. The company holds a total equity of $2.8 billion and plans to expand investments in AI infrastructure, expecting to report adjusted gross profit starting this quarter. Source: PRNewswire On April 28, Galaxy Digital's OTC associated address transferred 21,369 ETH to trading platforms, with a total value of $49.3 million, indicating the company's active trading behavior in the cryptocurrency market. Source: Jinse Finance On April 28, analysts rated Galaxy Digital as "Buy," with a target price of $38.18, showing market confidence in its future growth. Source: Reuters The cryptocurrency market is volatile, and AI investment has become a new growth point. Top Gainers in Pre-market US Stocks Cue BioPharma pre-market up 86.91%. Based on recent key news: On April 30, Cue Biopharma announced an exclusive licensing agreement with Ascendant Health Sciences to develop, manufacture, and commercialize Ascendant-221. This news significantly boosted the stock price. On April 30, the company announced a $30 million private placement, expected to be completed by May 4. This move enhanced market confidence in the company's financial status, further driving up the stock price. On April 30, Cue Biopharma appointed Shao-Lee Lin as the new CEO, and the market is optimistic about his leadership capabilities, positively impacting the stock price. The biopharmaceutical industry has performed strongly recently, with significant capital inflows. Esperion Therapeutics pre-market up 57.50%. Based on recent key news: On May 1, investment firm Archimed announced plans to privatize Esperion Therapeutics for up to $1.1 billion. According to the agreement, Esperion shareholders will receive $3.16 in cash per share, which is about a 58% premium over the company's last closing price. This news drove Esperion's stock price up over 55% in pre-market trading On May 1, Esperion shareholders may also receive up to $100 million in additional contingent payments over the next few years, provided that Esperion meets certain sales targets. This potential gain further enhances market confidence in the stock. As of the last closing on May 1, Esperion's market capitalization was approximately $514.81 million, with the transaction expected to complete in the third quarter of 2026, providing investors with a clear timeline and expectations. The privatization deal has driven a significant increase in the stock price. SOBR pre-market rose 43.86%. Based on recent key news: On April 30, SOBR Safe announced a merger agreement with Clean World Ventures. This news drove SOBR's stock price up 33.7% in after-hours trading, reaching $0.73. After the merger is completed, Clean World Ventures will hold approximately 98% of the new company's shares. This deal also includes obtaining approximately $5.5 million in third-party financing before completion, of which $2 million will be used for SOBR Safe's operating company. Source: Benzinga On May 1, Benzinga's stock rankings showed that SOBR stock exhibited a negative price trend across all time frames. Nevertheless, the merger news still had a positive impact on the stock price. Source: Benzinga The green energy technology industry is gaining attention